Kazia Therapeutics LTD income statement

In fiscal 2025, Kazia Therapeutics LTD reported revenue of $27,211, down 98.2% on the year before and net income of −$13.4m, or −$12.24 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Kazia Therapeutics LTD: income statement, annual
Fiscal year	2016Jun 2016	2017Jun 2017	2018Jun 2018	2021Jun 2021	2022Jun 2022	2023Jun 2023	2024Jun 2024	2025Jun 2025
Revenue	0	0	0	11	0	0	2	0
Research and development	7	8	8	11	15	10	11	5
Interest expense	0	0	0	—	—	—	—	—
Income before tax	−9	−8	−5	−7	−18	−14	−18	−15
Income tax	—	−0	−0	−0	−0	−0	−0	−1
Net income	−9	−8	−5	−6	−18	−14	−18	−13
Diluted EPS	—	—	—	−$13.37	−$34.25	−$18.90	−$16.65	−$12.24
Diluted shares (average)	—	—	—	—	—	—	1m	1m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: KZIA vs LYEL AIM vs KZIA IBIO vs KZIA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kazia Therapeutics LTD's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kazia Therapeutics LTD.